Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052956 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
A Phase 2 study, sponsored by University of Rochester.
- Not yet
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT06052956: Clinical Trial Phase 2 study, sponsored by University of Rochester.
NCT06052956 is a Phase 2 study that has not yet begun recruiting, run by University of Rochester. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06052956, a Phase 2 study, has not yet begun recruiting, sponsored by University of Rochester.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) standard of care abscess drainage. The primary endpoint is reduction in time to removal of the drainage catheter.
Primary Outcome
Drainage catheter output into the drainage bag will be noted daily by a member of the study team and the drainage catheter will be removed when output is reduced to \<5 mL/day, as is standard of care for this patient population. Time to drainage catheter removal (in days) will be recorded for all subjects.
Interventions
- DRUG Methylene Blue
- DEVICE Insertion of optical fiber
- DRUG Lipid Emulsion
- DEVICE Laser Illumination (pre-defined dose)
- DEVICE Optical Spectroscopy Measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 2 |
What is known before NCT06052956 opens enrollment
NCT06052956 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 5 interventions - of which Methylene Blue is the first listed.
NCT06052956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06052956 about?
NCT06052956 is a clinical study titled "Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses". The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care...
What is the current status of trial NCT06052956?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-07-15. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT06052956?
The interventions under investigation include: Methylene Blue (DRUG), Insertion of optical fiber (DEVICE), Lipid Emulsion (DRUG), Laser Illumination (pre-defined dose) (DEVICE), Optical Spectroscopy Measurement (DEVICE).
Who is sponsoring clinical trial NCT06052956?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06052956's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI